Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
— Steven Kates , Ph.D., Joins Company as Vice President, Regulatory Affairs — — David Caponera Appointed Head of Patient Advocacy and Patient Services — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading...
View HTML
Toggle Summary Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at the Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML
Toggle Summary Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus
— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2019-- Dicerna Pharmaceuticals, Inc . (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today...
View HTML
Toggle Summary Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update
— Initiated Screening of Participants to Enroll in the PHYOX™2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC – — Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for Treatment...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the...
View HTML
Toggle Summary Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial...
View HTML
Toggle Summary Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial
– Update Reflects Alignment with FDA on Path to Full Approval for Treatment of PH1 and Discussions Now Focusing on Appropriate Endpoints for PH2 and PH3 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML